Prosemble is pleased to announce the commencement of the immunogenicity phase of its mouse trials, conducted in partnership with TransCure BioServices, following the successful completion of the safety stage. This new phase will assess immune responses in CD34+...

We are proud to announce that Iryna Peretiazhko, currently completing her PhD at the Francis Crick Institute and Imperial College London under the supervision of Prof. Peter Rosenthal (Crick) and Dr Beeby (Imperial College), has had her article published in Nature —...

Prosemble recently participated in a competition run by the Düsseldorf regional government and is proud to share that we’ve been selected as a MedX@Düsseldorf Winners 2025—securing a booth at MEDICA 2025 in the coveted Start-up Park. MEDICA is one of the world’s...

On 17th July, Prosemble was awarded an AWS grant to support the assessment and implementation of large language models (LLMs) within our AI technology stack. This marks an exciting step forward in the evolution of our platform, particularly in enhancing its...

On 16th July, Prosemble had the opportunity to present to a panel of expert judges at Cancer Research UK as part of the grant awards process and Phase II selection for the Cancer Tech Accelerator (CTA). Our presentation was followed by a detailed Q&A session, with...

Prosemble recently attended the networking event at ICR Chelsea, where we had the opportunity to present our work and engage directly with leading scientists and innovators in the oncology space. It was a pleasure connecting with Dr. Jon Wilkinson, Director of...